Trial record 2 of 2934 for:    SUSTAIN 3

A Long-term Safety Study of Intranasal Esketamine in Treatment-resistant Depression (SUSTAIN-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02782104
Recruitment Status : Recruiting
First Posted : May 25, 2016
Last Update Posted : November 19, 2018
Information provided by (Responsible Party):
Janssen Research & Development, LLC

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : August 6, 2021
  Estimated Study Completion Date : October 31, 2022